Eli Lilly & Co. (LLY) Tops Q4 EPS by 29c, Lifts Outlook

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.09, $0.29 better than the analyst estimate of $1.80. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.35 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2023 EPS of $8.35-$8.55, versus the consensus of $8.28. Eli Lilly & Co. sees FY2023 revenue of $30.3-30.8 billion, versus the consensus of $30.55 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Imunon (IMNN) Tops Q2 EPS by 39c
• Intensity Therapeutics, Inc. (INTS) Misses Q2 EPS by 24c
• Cardinal Health (CAH) Tops Q4 EPS by 19c, Misses on Revenue; Offers FY27 EPS Guidance